All Q2 FY26 results →

J&

Johnson & Johnson

Q2 FY26Pharmaceuticals

Johnson & Johnson Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹231

Market cap₹5.6L Cr

P/E26.7

Updated29 May 2026

Read4 min read

What the Q2 FY26 call signalled

1 of 3 strong

RevenueModerate growth

MarginMargins slightly down

CapexCapex planned

The short version

- Johnson & Johnson expects double-digit top-line growth by the end of the decade, supported by strong momentum starting in 2026 with operational sales growth of 6.4% in Q1. - Johnson & Johnson expects double-digit revenue growth by the end of the decade, driven by a strong portfolio and pipeline.

From Johnson & Johnson's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth

Johnson & Johnson expects double-digit top-line growth by the end of the decade, supported by strong momentum starting in 2026 with operational sales growth of 6.4% in Q1.
Innovative Medicine showing robust growth with 7.4% operational sales increase driven by oncology, immunology, and neuroscience; 10 brands growing double digits.
Key growth drivers include new product launches such as ICOTYDE, TREMFYA, RYBREVANT, and INLEXZO, with ICOTYDE projected to be one of the largest products ever.
MedTech anticipates high single-digit growth contribution, with cardiovascular business growing rapidly due to acquisitions (Abiomed and Shockwave) and new technologies like Impella and IVL.
Continued expansion globally, increased market share, and new FDA approvals support sustained volume growth.

2 more points from Johnson & Johnson's call on revenue

Create a free account to keep reading this call

Profitability & Margins

Johnson & Johnson expects double-digit revenue growth by the end of the decade, driven by a strong portfolio and pipeline.
For 2026, operational sales growth guidance is raised to 5.9%-6.9%, with a midpoint of $100.2 billion (6.4%).
Reported sales growth guidance is 6.5%-7.5%, midpoint $100.8 billion (7%).
Adjusted pretax operating margin is expected to improve by at least 50 basis points in 2026.
Adjusted operational earnings per share guidance is raised to $11.30-$11.50 (5.7% growth at midpoint); reported adjusted EPS expected at $11.55 (7.1% growth).
Cost pressures and investments will be partly offset by operating leverage and revenue growth.

2 more points from Johnson & Johnson's call on margins

Create a free account to keep reading this call

See what Johnson & Johnson said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

Johnson & Johnson plans to invest $55 billion in U.S.-based manufacturing technology and R&D through early 2029.
By the end of 2025, approximately $12 billion (22% of the $55 billion) had already been invested.
Significant manufacturing investments are underway in North Carolina and Pennsylvania, with more announcements expected in upcoming quarters.
The company emphasizes ongoing investment in innovation, including heavier investment in new product launches and pipeline strengthening in the first half of 2026.

2 more points from Johnson & Johnson's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

As of Q1 2026, Johnson & Johnson ended the quarter with approximately $22 billion in cash and marketable securities and $55 billion in debt, resulting in net debt of about $33 billion.
Free cash flow in Q1 was approximately $1.5 billion, which is below the full-year projection due to timing.
The company maintains a strong financial position and cash flow generation, providing a competitive advantage for capital allocation and innovation investment.

2 more points from Johnson & Johnson's call on fundraising

Create a free account to keep reading this call

See what Johnson & Johnson said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant information on sales momentum and demand includes: - Vision business showed solid sales growth of 3.6% with expected acceleration through the year. - Surgical Vision grew 6%, with growth offset by competitive pressures in the U.S. but expected to accelerate in the second half of the year. - Contact lens sales rose 2.7%, driven by strong product families. - MedTech showed strong adoption of new products, including Impella devices (14% growth) and Shockwave (18.1% growth), with continued expansion globally and competitive market entrance.

2 more points from Johnson & Johnson's call on order book

Create a free account to keep reading this call

What Johnson & Johnson's management said in earlier quarters

Others in Pharmaceuticals this season

Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7

Compare:vs AstraZeneca PLC vs Novartis AG vs Novo Nordisk A/S

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Johnson & Johnson and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Johnson & Johnson Q2 FY26 results?

- Johnson & Johnson expects double-digit top-line growth by the end of the decade, supported by strong momentum starting in 2026 with operational sales growth of 6.4% in Q1. - Johnson & Johnson expects double-digit revenue growth by the end of the decade, driven by a strong portfolio and pipeline.

What is Johnson & Johnson share price analysis?

Johnson & Johnson currently shows a below-average growth signal. The stock trades at a P/E of 26.7 with a market cap of $555,586. Investors should review the full earnings analysis for detailed insights.

Is Johnson & Johnson planning capital expenditure?

- Johnson & Johnson plans to invest $55 billion in U.S.-based manufacturing technology and R&D through early 2029.

Keep Johnson & Johnson on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.